Clinical outcomes in heart failure with reduced left ventricular ejection fraction and good functional capacity: The illusion of stability

Ponikowski, 2016, Eur J Heart Fail, 18, 891, 10.1002/ejhf.592 Jones, 2019, Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis, Eur J Heart Fail, 21, 1306, 10.1002/ejhf.1594 Butler, 2016, Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure, Eur J Heart Fail, 18, 350, 10.1002/ejhf.507 Kocabaş, 2020, Adherence to guideline-directed medical and device therapy in outpatients with heart failure with reduced ejection fraction: the ATA study, Anatol J Cardiol, 24, 32 Gheorghiade, 2012, Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF, Congest Heart Fail, 18, 9, 10.1111/j.1751-7133.2011.00250.x Arena R1, 2011, Cardiopulmonary exercise testing is a core assessment for patients with heart failure, Congest Heart Fail, 17, 115, 10.1111/j.1751-7133.2011.00216.x Guazzi, 2012, Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations, Circulation, 126, 2261, 10.1161/CIR.0b013e31826fb946 Hicks, 2015, J Am Coll Cardiol, 66, 403, 10.1016/j.jacc.2014.12.018 Riebe, 2018 Mogensen, 2018, Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in Heart Failure trial (PARADIGM-HF), Eur J Heart Fail, 20, 760, 10.1002/ejhf.1139 Solomon, 2016, Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial, JACC Heart Fail, 4, 816, 10.1016/j.jchf.2016.05.002 Januzzi, 2012, Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section, Eur Heart J, 33, 2265, 10.1093/eurheartj/ehs191 Kociol, 2010, Troponin elevation in heart failure prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, 56, 1071, 10.1016/j.jacc.2010.06.016 Murphy, 2021, Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction, Circ Heart Fail, 14, e008410, 10.1161/CIRCHEARTFAILURE.120.008410 Wirtz, 2020, Real-world analysis of guideline-based therapy after hospitalization for heart failure, J Am Heart Assoc, 9, e015042, 10.1161/JAHA.119.015042 Fiuzat, 2020, Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical trial, JAMA Cardiol, 5, 757, 10.1001/jamacardio.2020.0640 Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312 Konstam, 2009, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Lancet, 374, 1840, 10.1016/S0140-6736(09)61913-9 Bristow, 1996, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators, Circulation, 94, 2807, 10.1161/01.CIR.94.11.2807 McMurray, 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077